Status:
COMPLETED
Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia
Lead Sponsor:
Mazandaran University of Medical Sciences
Conditions:
Pulmonary Artery Pressure
Thalassemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The goal of this clinical trial is to learn whether L-glutamine can help lower pulmonary artery pressure in adults with non-transfusion-dependent thalassemia (NTDT). The main questions it aims to ans...
Eligibility Criteria
Inclusion
- Adults (≥18 years), any sex.
- Diagnosis of non-transfusion-dependent β-thalassemia (NTDT).
- Pulmonary artery pressure (PAP) \> 35 mmHg estimated by Doppler echocardiography at screening.
- Able and willing to provide written informed consent.
- On a stable standard-of-care regimen (e.g., chelation and/or hydroxyurea) per treating physician judgment.
Exclusion
- Age \<18 years.
- Refusal or inability to provide informed consent.
- Hepatic dysfunction: ALT \>3× upper limit of normal.
- Renal dysfunction: serum creatinine \>2× upper limit of normal.
- Known hypersensitivity to L-glutamine.
- Pregnancy or breastfeeding.
- Use of amino-acid/protein supplements within the past 3 months.
- History of other cardiac diseases associated with pulmonary hypertension (per investigator assessment).
Key Trial Info
Start Date :
August 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 27 2025
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT07210450
Start Date
August 15 2023
End Date
September 27 2025
Last Update
October 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bu'Ali Sina Hospital
Sari, Mazandaran, Iran, 4815738477